GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
==== Pharmacological significance ==== ACE is a pharmaceutical target of ACE inhibitor drugs, which decrease the rate of conversion of angiotensin I to angiotensin II, and of angiotensin II receptor antagonists which block angiotensin II AT1 receptors. Angiotensin II results in increased inotropy, chronotropy, catecholamine and sensitivity, aldosterone levels, vasopressin levels, and cardiac remodeling and vasoconstriction through AT1 receptors on peripheral vessels (conversely, AT2 receptors impair cardiac remodeling). This is why ACE inhibitors and ARBs help to prevent remodeling that occurs secondary to angiotensin II and are beneficial in congestive heart failure.
{\displaystyle {\begin{cases}\rho {\dfrac {\partial \mathbf {u} }{\partial t}}+\rho (\mathbf {u} \cdot \nabla )\mathbf {u} -\nabla \cdot {\boldsymbol {\sigma }}(\mathbf {u} ,p)=\mathbf {f} &{\text{ in }}\Omega \times (0,T)\\\nabla \cdot \mathbf {u} =0&{\text{ in }}\Omega \times (0,T)\\\mathbf {u} =\mathbf {g} &{\text{ on }}\Gamma _{D}\times (0,T)\\{\boldsymbol {\sigma }}(\mathbf {u} ,p){\hat {\mathbf {n} }}=\mathbf {h} &{\text{ on }}\Gamma _{N}\times (0,T)\\\mathbf {u} (0)=\mathbf {u} _{0}&{\text{ in }}\Omega \times \{0\}\end{cases}}}
777 was the owner of low-cost carrier Flair Airlines. In June 2022, the Canadian Transportation Agency ruled that Flair is a Canadian airline and can fly domestically, as 777 owns 25% of the shares and had limited its influence on the board since the beginning of the CTA investigation. On March 11, 2023, Airborne Capital Ltd. seized four of its planes operated by Flair over alleged non-payment. In a press conference, Flair CEO Stephen Jones suggested the seizures were motivated by competitors, and that the airline owed around US$1 million on the leases, and was in the process of making payment when the seizures occurred. The lessor, Airborne alleged that Flair had repeatedly missed payments amounting to several millions of dollars over a period of five months. Flair used other aircraft to continue to operate its schedule. In January 2024, it was reported that the lessors had filed claims at the UK High Court for costs and that there had been outstanding payments of $1.8 million on the four aircraft when notice of default was served. In August 2024, interim CEO Maciej Wilk said that 777's stake in Flair was down to 10% and the company's involvement was mostly as a lender, having no presence in the boardroom.
In pharmaceutical industry, stability testing is a process that is used to determine the quality of a drug substance or drug product over a period of specified time under specific environmental conditions. With stability testing, pharmaceutical industry inspects the quality of drug substances and drug products as per the guidelines outlined by US Food and Drug Administration and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use to make sure that they retained the quality over the period of time. Stability testing depends upon the environmental factors like, light source, humidity and ambient temperature as well as the physical and chemical properties of the active drug product.
Sources: en.wikipedia.org
primary reconstruction: the replacement of breast tissues damaged by trauma (blunt, penetrating, blast), disease (breast cancer), and failed anatomic development (tuberous breast deformity). revision and reconstruction: to revise (correct) the outcome of a previous breast reconstruction surgery. primary augmentation: to aesthetically augment the size, form, and feel of the breasts. The operating room time of post–mastectomy breast reconstruction, and of breast augmentation surgery is determined by the procedure employed, the type of incisions, the breast implant (type and materials), and the pectoral locale of the implant pocket. Recent research has indicated that mammograms should not be done with any greater frequency than that used in normal procedure in patients undergoing breast surgery, including breast implant, augmentation, mastopexy, and breast reduction.
Diode-array spectrophotometers differed from the original spectrophotometer created by Beckman because it was the first single-beam microprocessor-controlled spectrophotometer that scanned multiple wavelengths at a time in seconds. It irradiates the sample with polychromatic light which the sample absorbs depending on its properties. Then it is transmitted back by grating the photodiode array which detects the wavelength region of the spectrum. Since then, the creation and implementation of spectrophotometry devices has increased immensely.
==== Lifestyle ==== Physical activity can reduce the risk of cardiovascular disease, and people at risk are advised to engage in 150 minutes of moderate or 75 minutes of vigorous intensity aerobic exercise a week. Keeping a healthy weight, drinking alcohol within the recommended limits, and quitting smoking reduce the risk of cardiovascular disease. Substituting unsaturated fats such as olive oil and rapeseed oil instead of saturated fats may reduce the risk of myocardial infarction, although there is not universal agreement. Dietary modifications are recommended by some national authorities, with recommendations including increasing the intake of wholegrain starch, reducing sugar intake (particularly of refined sugar), consuming five portions of fruit and vegetables daily, consuming two or more portions of fish per week, and consuming 4–5 portions of unsalted nuts, seeds, or legumes per week. The dietary pattern with the greatest support is the Mediterranean diet. Vitamins and mineral supplements are of no proven benefit, and neither are plant stanols or sterols. Public health measures may also act at a population level to reduce the risk of myocardial infarction, for example by reducing unhealthy diets (excessive salt, saturated fat, and trans-fat) including food labeling and marketing requirements as well as requirements for catering and restaurants and stimulating physical activity. This may be part of regional cardiovascular disease prevention programs or through the health impact assessment of regional and local plans and policies.
Southern Rhodesia was represented in the Dodecanese Campaign of September–November 1943 by the Long Range Desert Group, which was withdrawn from the North African front in March 1943. After retraining for mountain operations in Lebanon, the LRDG moved in late September to the Dodecanese island of Kalymnos, north-west of Kos and south-east of Leros, off the coast of south-west Turkey. In the fall-out from the Armistice of Cassibile between Italy and the Allies, which had been concluded in the first week of September, the Allies were attempting to capture the Dodecanese so the islands could be used as bases against the German-occupied Balkans. Most of the Italian forces had changed sides; the LRDG found itself in an infantry role, acting as a mobile reserve for Italian troops. The Germans swiftly mobilised to expel the Allied forces and launched heavy air assaults on Kos and Leros. Without fighter support, the islands' defence was soon precarious; the LRDG and the rest of the troops on Kalymnos were withdrawn to Leros on 4 October after the Germans won the Battle of Kos. German air assaults on Leros intensified during late October, and at dawn on 12 November 1943 the Germans attacked Leros by sea and air. During the ensuing Battle of Leros, the LRDG Rhodesians at Point 320, commanded by Rhodesian Captain J R Olivey, spiked their position's guns and withdrew before counter-attacking and retaking the point the next day. They held that position for three more days, during which they learned that the Germans were winning the battle.
== Chemistry == The substance is a white crystalline powder. It is freely soluble in methanol and acetone; soluble in water, ethanol, 0.01 M hydrochloric acid, and 0.01 M sodium hydroxide; sparingly soluble in isopropyl alcohol and acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.